# W1131 TFA

Cat. No.: HY-153190A Molecular Formula:  $C_{25}H_{20}F_3N_5O_6$ 

Molecular Weight: 543.45

Target: Ferroptosis; STAT

Pathway: Apoptosis; JAK/STAT Signaling; Stem Cell/Wnt

Storage: Powder -20°C 3 years

> 4°C 2 years

In solvent -80°C 6 months

> -20°C 1 month

**Product** Data Sheet

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (184.01 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.8401 mL	9.2005 mL	18.4010 mL
	5 mM	0.3680 mL	1.8401 mL	3.6802 mL
	10 mM	0.1840 mL	0.9200 mL	1.8401 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (4.60 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (4.60 mM); Clear solution; Need ultrasonic

## **BIOLOGICAL ACTIVITY**

Description W1131 TFA is a potent STAT3 inhibitor that induces ferroptosis. W1131 inhibits cancer progression in subcutaneous

> xenograft, organoid, and PDX models of gastric cancer. W1131 effectively alleviates cancer cell chemoresistance to 5-FU (HY- $90006).\ W1131\ regulates\ the\ cell\ cycle,\ DNA\ damage\ response,\ and\ oxidative\ phosphorylation,\ including\ the\ IL6-JAK-STAT3$

pathway and the ferroptosis pathway<sup>[1]</sup>.

STAT3<sup>[1]</sup>IC<sub>50</sub> & Target

### **REFERENCES**

1]. Ouyang S, et al. Inhibition o lun;52:102317.	f STAT3-ferroptosis negative	regulatory axis suppresses tumo	r growth and alleviates chemoresistance in ga	stric cancer. Redox Biol. 2022
		ot been fully validated for me	dical applications. For research use only.	
	Tel: 609-228-6898 Address: 1	Fax: 609-228-5909 Deer Park Dr, Suite Q, Monmo	E-mail: tech@MedChemExpress.com uth Junction, NJ 08852, USA	

Page 2 of 2 www.MedChemExpress.com